Tag Archives: BIO Investor Forum

Kinase Drug Development – Making Progress

The kinase inhibition field has had plenty of ups and downs and over the last decade, but when we take a look at recent approvals and NDA filings there seems to be a strengthening of the field. There are now 16 kinase inhibitors that have been approved and five seeking regulatory approval in the next few months. The last two years in particular has been a boom for the KIs, with seven approvals, three of which target Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum: The New Kids on the Biotech Block

desert

Where should biotech start-ups look for funding in the venture capital desert that is becoming the new normal? The panel The New Kids on the Biotech Block: Trends in Early-Stage Financing kicked off the 11th Annual BIO Investor Forum and focused on non-traditional early-stage investors and deal structures. Moderated by Jeron Eaves, a senior practice executive with Campbell Alliance, the panel highlighted companies that have secured financing from creative sources, like patient advocacy groups and venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Cancer Stem Cell Therapy: Real Or Just Hype?

Stem Cell Therapy

Also known as tumor-initiating cells, cancer stem cells (CSC) have unique capability endemic to stem cells of self-renewal and differentiation, thereby causing tumor relapse and/or metastatis. While traditional cancer treatments focus on tumor shrinkage, it’s a distinct possibility that these agents do not effectively destroy all of the CSCs, causing the tumor to reappear. The CSC theory is relatively new, so the treatment pipeline is still in its early stages. Nathan Sadeghi-Nejad, a contributor to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

#BIF2012 Company Snapshot: Chimerix

Chimerix

Our next Company Snapshot for next week’s BIO Investor Forum is Chimerix. They will be presenting on Tuesday, at 1:30pm, and will also be participating in a panel at the event, Choose Your Own Adventure — Late Stage Private Company Decisions on Wednesday. To learn more about the company before you get onsite, continue reading! Company Snapshot What is your company’s lead product or technology? Chimerix’s lead product is CMX001, a novel, broad-spectrum, oral antiviral that inhibits double-stranded Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

#BIF2012 Company Snapshot: Profil Institute for Translational Medicine

profil_trans_med

For the next Company Snapshot for the BIO Investor Forum, we’ve spoken with one of the presenting companies at the event, Profil Institute for Translational Medicine, Inc. To find out more about this organization and what they’re doing for biotech, please read below! You’ll be able to see their presentation onsite, Wednesday 10/10 at 9:30am in the Presidio Room.   Company Snapshot What is your company’s lead product or technology? Based on collaborations with biopharma, Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,